MGNX - MacroGenics reports that AML patients benefit from flotetuzumab immunotherapy

MacroGenics (MGNX) publishes a report on the role of Flotetuzumab (also known as MGD006) in the immunotherapy of TP53-positive acute myeloid leukemia ((AML)) in a journal of the American Society of Hematology.Flotetuzumab is an investigational, clinical-stage bispecific DART molecule that recognizes both CD123 on leukemic cells and CD3 on T cells, with the intended result of T-cell-mediated killing of leukemic blasts. It has previously been shown that an inflammatory (IFN-?-related) gene expression signature in patients with AML correlated with a lack of response to induction chemotherapy. The same gene signature was shown to be associated with an increased probability of this subset of patients to respond to flotetuzumab.As further described in the article titled “TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in AML,” AML with TP53 abnormalities was also associated with immune infiltration in the tumor microenvironment ((TME)); moreover, patients with TP53 abnormalities derived benefit from flotetuzumab immunotherapy. The results

For further details see:

MacroGenics reports that AML patients benefit from flotetuzumab immunotherapy